Amgen reported strong Q2 results with 4% revenue growth and a 17% increase in non-GAAP EPS, alongside raised full-year guidance. The successful launches of new products and continued international growth outweigh concerns about competition and management changes, suggesting positive investor sentiment in the short term.

[1]